Effectiveness and Safety of a Moisturizer Containing Centella Asiatica Extract, Ceramide NP, and Panthenol for Erythema and Skin Barrier in Erythematotelangiectatic Rosacea: A Randomized Controlled Trial Study.

title: "A Centella Asiatica Moisturizer Shows Faster Redness Improvement in Rosacea: What the Randomized Trial Found"

description: "A 75-patient randomized controlled trial tested a moisturizer with Centella asiatica, ceramide NP, and panthenol alongside oral minocycline for erythematotelangiectatic rosacea."

date: "2025-01-01"

category: "research-update"

studyType: "RCT"

sampleSize: 75

pubmedId: "42876425"

TL;DR

A small randomized controlled trial (n=75) found that a moisturizer containing Centella asiatica extract, ceramide NP, and panthenol, used alongside oral minocycline, produced faster improvements in facial redness and skin hydration than the control arm in patients with erythematotelangiectatic rosacea. Evidence tier: B (single small RCT, not yet replicated).

What the study found

Erythematotelangiectatic rosacea is a chronic, relapsing inflammatory skin condition characterized by persistent facial flushing, visible blood vessels, and sensitive, compromised skin. Beyond the physical symptoms, the condition often carries a meaningful psychological burden. Because the skin barrier is frequently disrupted in rosacea, moisturization is widely considered part of routine management, which makes the choice of moisturizer a practical clinical question. This trial was designed to test whether a specific formulation offers measurable advantages.

The researchers enrolled 75 Chinese adults with erythematotelangiectatic rosacea and randomized 39 to the experimental group and 36 to the control group. All participants took oral minocycline 50 mg once daily and applied a moisturizer twice daily. The experimental group used the formulation containing Centella asiatica extract, ceramide NP, and panthenol. Outcomes were measured at baseline, day 7, day 14, and day 28, and included facial redness imaging, stratum corneum hydration (SCH), transepidermal water loss (TEWL), and the Clinician's Erythema Assessment (CEA). Patients also self-reported symptoms using the Patient's Self-Assessment (PSA) scale and the Rosacea-specific Quality-of-life instrument (RosQol).

The experimental group showed significantly greater changes from baseline to day 28 in the a* value (a colorimetric measure of redness), facial red area, stratum corneum hydration, and RosQol scores. In other words, the moisturized group showed larger and faster shifts on these measures. The authors also reported that the mean rank of the CEA was significantly higher in the control group at day 28, which indicates a different pattern on the clinician-rated erythema score. This is a notable mixed result: the clinician assessment did not favor the experimental formulation in the same way the imaging and hydration measures did, and the trial summary does not offer a single unified explanation for that divergence.

Safety data were reported as favorable. All adverse events were described as mild and self-limiting. The study does not establish long-term safety beyond the 28-day window, and it does not isolate the contribution of each active ingredient, so the findings apply to the combined formulation as tested. Because the control arm also received minocycline and a moisturizer, the study compares two moisturizer approaches layered on the same background therapy rather than testing the moisturizer against no adjunct.

It is also worth being direct about the limits of this evidence. This is a single trial of 75 participants from one population, and it has not been independently replicated. The primary strength is the randomized design and multi-timepoint measurement. The main weaknesses are the modest sample, the 28-day duration, and the mixed clinician-rated outcome. Findings like these are useful for generating hypotheses and informing clinical discussion, but they are not yet sufficient to establish the formulation as a standard of care.

What this means for you

Moisturization is a reasonable part of rosacea management, but this trial does not prove a specific product is superior. The active ingredients tested (Centella asiatica, ceramide NP, panthenol) are plausible skin-barrier supports, yet the evidence for this exact combination is limited to one small study.

Discuss options with a dermatologist. Because rosacea treatment is individualized, a clinician can weigh a moisturizer like this against other adjunctive choices and your specific symptoms.

Keep expectations calibrated. The trial measured changes over four weeks alongside oral minocycline. Results may differ with other treatment regimens, skin types, or longer use.

Watch for irritation. Although adverse events were mild in this trial, any new topical product can irritate sensitive skin. Patch testing and introducing one product at a time are sensible precautions.

Study details

Field	Detail
Study type	Randomized controlled trial
Condition	Erythematotelangiectatic rosacea
Sample size	75 (39 experimental, 36 control)
Population	Chinese patients with erythematotelangiectatic rosacea
Intervention	Moisturizer with Centella asiatica extract, ceramide NP, and panthenol, twice daily, plus oral minocycline 50 mg daily
Comparator	Control moisturizer, twice daily, plus oral minocycline 50 mg daily
Duration	28 days
Outcomes	a* value, facial red area, SCH, TEWL, CEA, PSA, RosQol
Key finding	Greater improvement in redness imaging, hydration, and RosQol in experimental group; higher CEA mean rank in control group at day 28
Safety	All adverse events mild and self-limiting
Evidence tier	B (single small RCT, unreplicated)
Journal	Skin Research and Technology

Sources

1. Study details and abstract: Skin Research and Technology (official journal of ISBS, ISDIS, and ISSI). PubMed. https://pubmed.ncbi.nlm.nih.gov/42876425/

ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.